Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma. (27th January 2021)

• Record Type: Journal Article
• Authors: Lasarte-Cia, Aritz; Lozano, Teresa; Cano, David; Martín-Otal, Celia; Navarro, Flor; Gorraiz, Marta; Casares, Noelia; Vivas, Isabel; Lasarte, Juan José
• Other Names: Tao Junyan Academic Editor.
• Is Part Of: BioMed research international. Volume 2021(2021)
• Publication Date: 2021-01-27
• Subjects: Medicine -- Periodicals; Biology -- Periodicals; Biotechnology -- Periodicals; Life sciences -- Periodicals; 610.5
• DOI: 10.1155/2021/8852233
• Languages: English
• ISSNs: 2314-6133

Abstract

Abstract : Background/Aim . Irreversible electroporation (IRE) showed promising results for small-size tumors and very early cancers. However, further development is needed to evolve this procedure into a more efficient ablation technique for long-term control of tumor growth. In this work, we show that it is possible to increase the antitumor efficiency of IRE by simmultaneously injecting c-di-GMP, a STING agonist, intratumorally. Materials and Methods . Intratumoral administration of c-di-GMP simultaneously to IRE was evaluated in murine models of melanona (B16.OVA) and hepatocellular carcinoma (PM299L). Results . The combined therapy increased the number of tumor-infiltrating IFN- γ /TNF- α -producing CD4 and CD8 T cells and delayed tumor growth, as compared to the effect observed in groups treated with c-di-GMP or IRE alone. Conclusion . These results can lead to the development of a new therapeutic strategy for the treatment of cancer patients refractory to other therapies.